ClinicalTrials.gg
RecruitingNCT06938464Updated Apr 27, 2025

Preventive Effect of Probiotics in GDM

An interventional study of Probiotics and Placebo in Gestational Diabetes Mellitus (GDM), sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Registered 1 year 5 months after the study started (first participant enrolled Oct 2023, registered Apr 2025).
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.

Planned enrollment
15th of 39
334 · median 291
Started
2023
with 5 others
No phase
36 of 68
7 open now
Primary completion
2025-11
later than 8 of 22 live
Registered
61st of 68
by date
Lead sponsor
9 of 68
Women's Hospital School Of Medicine Zhejiang University

Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 15th largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2023, is one of 36 with no phase, reaches primary completion later than 8 of the 22 other live ones, and was the 61st registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Diabetes, Gestational with a site in China, or all of them as a file.
02

Study summary

Gut microbiota is instrumental in the microbial and metabolic network of pregnant women, and is potentially related with gestational diabetes. Perinatal probiotic intervention contributes to improved glucose regulation during pregnancy. Our randomized, double-centered, placebo-controlled study is planned to recruit 334 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly probiotic powder per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about neonatal weight will be registered.

03

Conditions studied

  • Gestational Diabetes Mellitus (GDM)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women who meet the high-risk indicators for GDM and agree to participate in this study.

    1. included between 12-16 gestational weeks
    2. A woman was considered high risk when her pre-pregnancy ≥ 24 kg/m\^2, having family history of diabetes (type 1 or 2), GDM or PCOS (polycystic ovary syndrome) history, history of delivering macrosomia or stillbirth, or glucose in urine (+)

Exclusion criteria

Exclusion Criteria:

  1. Taking probiotics or prebiotics within the past month
  2. Have a history of allergies to the drug components or similar drugs in this study
  3. Having long-term smoking or drinking habits
  4. Type 1 or type 2 diabetes patients with definite diagnosis before pregnancy
  5. Diseases in other important organs such as heart, liver, and kidney
  6. with clear digestive system diseases
  7. Multiple pregnancy
  8. with mental or cognitive impairments who are unable to complete this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
334 participants (estimated)

Study arms

  • Active comparator
    Probiotics

    Probiotic powder 1 bag per day, as well as health guidance about diet and exercise. From recruitment until OGTT.

    Dietary Supplement: Probiotics

  • Placebo comparator
    Placebo

    Placebo 1 bag per day. Similar health guidance about diet and exercise. From recruitment until OGTT

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotics

    Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid

  • Dietary supplementPlacebo

    placebo with similar appearance and smell but not containing probiotics

06

What researchers measure

Primary outcomes

  1. the incidence of gestational diabetes

    The number of cases and incidence of gestational diabetes according to OGTT

    Time frame: 24-28th weeks gestation

Secondary outcomes

  1. The incidence of macrosomia

    macrosomia refers to a newborn weighs more than 4 kg)

    Time frame: Delivery

  2. Weight gain during pregnancy (kg)

    Weight gain during pregnancy (kg) = Maternal weight at delivery - weight pre-pregnancy

    Time frame: Delivery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 24 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 22, 2025
StartActual
Oct 27, 2023
Primary completionEst.
Nov 1, 2025
CompletionEst.
Nov 1, 2026
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06938464
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Collaborators
Quzhou Maternal and Child Health Care Hospital
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Oct 27, 2023
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Apr 27, 2025

Study contacts

Danqing Chen, Prof
Contact
Chendq@zju.edu.cn
86571-87061501
Xinning Chen
Contact
jhviolet@163.com
+8618817362544

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion